ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency

This study has been completed.
Study NCT00161304.   Last updated on September 11, 2005.   Information provided by Urological Sciences Research Foundation

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency
Official Title  Effects of Testosterone Administration on Tissues of Men With A.D.A.M. (Androgen Deficiency of Aging Men)
Brief Summary

The T-001 study is a placebo-controlled investigation of the effects of injectable testosterone replacement therapy on prostate tissues of aging men with low testosterone levels. The primary objectives of the study are to measure the changes in tissue hormones and other biomarkers in the prostate tissue specimens.

Detailed Description
Study Phase Phase II, Phase III
Study Type  Interventional
Study Design  Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary Outcome Measure 
Secondary Outcome Measure 
Condition  Men With Low Testosterone Levels
Intervention  Drug: Testosterone Enanthate
MEDLINE PMIDs
Links Related Info This link exits the ClinicalTrials.gov site
Recruitment Information Fields
Recruitment Status  Completed
Enrollment  44
Start Date  April 2003
Completion Date November 2004
Eligibility Criteria 

Inclusion Criteria:Inclusion Criteria

  1. Male aged 50-80 years of age, ambulatory, and in good general physical and mental health.
  2. Clinical diagnosis of hypogonadism defined as a serum testosterone level less than 300 ng/dl on a morning serum sample during the screening period.
  3. Answering yes to question 1 or 7 or to any three questions total on the Morley index at baseline.
  4. PSA <10 ng/ml
  5. Subject is able to give informed consent.

Exclusion Criteria

  1. Failure to meet the criteria for inclusion
  2. History of allergy to testosterone or any components of the delivery system.
  3. Significant abnormalities on pre-study clinical examination or laboratory measurements.
  4. Treatment with any investigational drug during the previous month.
  5. Drug or alcohol abuse or dependence.
  6. Concurrent use of testosterone and or any hormonal therapy, including health food supplements and herbal products, that could alter serum testosterone levels or affect the prostate (e.g. gonadotropic releasing hormone agonists, testosterone antagonists, anabolic steroids, DHEA, androstenedione, PC-SPES, chrysin and tribulus terrestris,). Use of alpha-reductase inhibitors or prostate phytotherapy within the past 3 months.
  7. Use of antidepressant medications, oral glucocorticoids, or opioids.
  8. PSA > 10 ng/ml and/or prostate biopsy positive for cancer at screening. Any patient in whom there is a suspicion of prostate cancer must undergo appropriate testing to rule out cancer prior to entry into the study.
  9. IPSS score  20.
  10. History of malignancy of any type (except basal cell carcinoma).
  11. Patients with uncontrolled diabetes.
  12. Patients with known or suspected bleeding disorder. Concurrent use of Coumadin and other anticoagulants at the time of biopsy or if discontinuation of such therapy prior to biopsy poses a risk to the patient.
  13. Inability of the patient to provide written informed consent for any reason, including legal incompetence, language or comprehension difficulty, and psychological, psychiatric or emotional factors.
  14. Inability of the patient to have transrectal ultrasonography with biopsy (for any reason).
  15. A history of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the patient.
Gender Male
Ages 50 Years and older
Accepts Healthy Volunteers Yes
Contacts ††
Location Countries  United States
Administrative Information Fields
NCT ID  NCT00161304
Organization ID T-001
Secondary IDs ††
Study Sponsor  Urological Sciences Research Foundation
Collaborators †† Solvay Pharmaceuticals
Watson Pharmaceuticals
Investigators 
Principal Investigator:     Leonard S Marks, M.D.     Urological Sciences Research Foundation    
Information Provided By Urological Sciences Research Foundation
Verification Date November 2004
First Received Date  September 8, 2005
Last Updated Date September 11, 2005

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers